Touyun Biotech Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Touyun Biotech Group şirketinin kazançları yıllık ortalama -2.2% oranında azalırken, Packaging sektörünün kazançları yıllık 10.3% oranında artan oldu. Gelirler yıllık ortalama 7.9% oranında azalan oldu.

Anahtar bilgiler

-2.2%

Kazanç büyüme oranı

1.5%

EPS büyüme oranı

Packaging Sektör Büyümesi	11.6%
Gelir büyüme oranı	-7.9%
Özkaynak getirisi	n/a
Net Marj	-137.4%
Son Kazanç Güncellemesi	30 Jun 2024

Yakın geçmiş performans güncellemeleri

Recent updates

Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Sep 15

Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jul 17

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Apr 22

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Apr 08

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

Feb 07

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

Dec 18

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

Sep 19

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

Jul 28

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

Mar 12

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

Jan 15

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

Jan 15

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

Dec 11

Gelir ve Gider Dağılımı

Touyun Biotech Group nasıl para kazanır ve harcar. LTM bazında en son bildirilen kazançlara dayanmaktadır.

Kazanç ve Gelir Geçmişi

SEHK:1332 Gelir, gider ve kazançlar (HKD Millions )
Tarih	Gelir	Kazançlar	G+A Giderleri
30 Jun 24	170	-233	142
31 Mar 24	184	-251	143
31 Dec 23	199	-269	144
30 Sep 23	226	-231	151
30 Jun 23	253	-194	158
31 Mar 23	284	-196	160
31 Dec 22	316	-198	163
30 Sep 22	314	-149	156
30 Jun 22	313	-100	150
31 Mar 22	298	-86	148
31 Dec 21	284	-73	145
30 Sep 21	268	-110	145
30 Jun 21	252	-148	145
31 Mar 21	229	-158	142
31 Dec 20	207	-169	139
30 Sep 20	230	-190	137
30 Jun 20	252	-212	134
31 Mar 20	298	-206	148
31 Dec 19	343	-201	162
30 Sep 19	357	-221	186
30 Jun 19	371	-242	210
31 Mar 19	360	-248	226
31 Dec 18	349	-254	241
30 Sep 18	364	-245	230
30 Jun 18	378	-236	218
31 Mar 18	348	-240	195
31 Dec 17	318	-245	172
30 Jun 17	163	-917	139
31 Mar 17	62	-1,006	114
31 Dec 16	-38	-1,095	89
30 Jun 16	58	-357	110
31 Mar 16	172	-51	109
31 Dec 15	286	255	107
30 Sep 15	309	302	80
30 Jun 15	332	349	54
31 Mar 15	365	180	54
31 Dec 14	397	10	54
30 Sep 14	405	10	55
30 Jun 14	414	10	55
31 Mar 14	425	11	54
31 Dec 13	436	13	53

Kaliteli Kazançlar: 1332 şu anda kârlı değil.

Büyüyen Kar Marjı: 1332 şu anda kârlı değil.

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Kazanç Eğilimi: 1332 kârlı değildir ve zararlar son 5 yılda yılda 2.2% oranında artmıştır.

Büyüme Hızlandırma: 1332 'un son bir yıldaki kazanç büyümesinin 5 yıllık ortalamasıyla karşılaştırılması mümkün değil çünkü şu anda kârlı değil

Kazançlar vs. Sektör: 1332 kârlı olmadığından, geçmiş yıl kazanç büyümesinin Packaging sektörüyle ( 20.9% ) karşılaştırılması zorlaşıyor.

Özkaynak Getirisi

Yüksek ROE: 1332 'un yükümlülükleri varlıklarından fazla olduğundan Özsermaye Getirisi'ni hesaplamak zordur.

Touyun Biotech Group Geçmiş Kazanç Performansı

Geçmiş kriter kontrolleri 0/6

Anahtar bilgiler

Yakın geçmiş performans güncellemeleri

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

Touyun Biotech Group Limited to Report First Half, 2024 Results on Aug 23, 2024

Full year 2023 earnings released: HK$0.096 loss per share (vs HK$0.071 loss in FY 2022)

Touyun Biotech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

First half 2023 earnings released: HK$0.03 loss per share (vs HK$0.031 loss in 1H 2022)

Recent updates

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

Revenues Not Telling The Story For Touyun Biotech Group Limited (HKG:1332) After Shares Rise 29%

Non-Executive Director recently sold HK$111k worth of stock

First half 2024 earnings released: HK$0.017 loss per share (vs HK$0.03 loss in 1H 2023)

New major risk - Negative shareholders equity

Touyun Biotech Group Limited to Report First Half, 2024 Results on Aug 23, 2024

Touyun Biotech Group Limited's (HKG:1332) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Risks Still Elevated At These Prices As Touyun Biotech Group Limited (HKG:1332) Shares Dive 28%

Would Touyun Biotech Group (HKG:1332) Be Better Off With Less Debt?

Full year 2023 earnings released: HK$0.096 loss per share (vs HK$0.071 loss in FY 2022)

Touyun Biotech Group Limited to Report Fiscal Year 2023 Results on Mar 28, 2024

What Touyun Biotech Group Limited's (HKG:1332) 46% Share Price Gain Is Not Telling You

New major risk - Share price stability

Non-Executive Director recently sold HK$173k worth of stock

Some Touyun Biotech Group Limited (HKG:1332) Shareholders Look For Exit As Shares Take 42% Pounding

New minor risk - Market cap size

First half 2023 earnings released: HK$0.03 loss per share (vs HK$0.031 loss in 1H 2022)

Touyun Biotech Group (HKG:1332) Is Carrying A Fair Bit Of Debt

First half 2023 earnings released: HK$0.03 loss per share (vs HK$0.031 loss in 1H 2022)

Touyun Biotech Group Limited to Report First Half, 2023 Results on Aug 25, 2023

Risks To Shareholder Returns Are Elevated At These Prices For Touyun Biotech Group Limited (HKG:1332)

New major risk - Share price stability

Non-Executive Director recently sold HK$110k worth of stock

Full year 2022 earnings released

Less than half of directors are independent

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

First half 2022 earnings released: HK$0.031 loss per share (vs HK$0.022 loss in 1H 2021)

Touyun Biotech Group Limited Announces Company Secretary Changes, Effective August 02, 2022

Touyun Biotech Group (HKG:1332) Is Making Moderate Use Of Debt

Less than half of directors are independent

Full year 2021 earnings released: EPS: HK$0.026 (vs HK$0.063 loss in FY 2020)

Touyun Biotech Group Limited to Report Fiscal Year 2021 Final Results on Apr 29, 2022

Touyun Biotech Group Limited to Report Fiscal Year 2021 Results on Mar 31, 2022

Here's Why Touyun Biotech Group (HKG:1332) Can Afford Some Debt

First half 2021 earnings released: HK$0.022 loss per share (vs HK$0.032 loss in 1H 2020)

Full year 2020 earnings released: HK$0.063 loss per share (vs HK$0.082 loss in FY 2019)

Full year 2020 earnings released: EPS HK$0.063 (vs HK$0.082 loss in FY 2019)

China Touyun Tech Group Limited to Report Fiscal Year 2020 Results on Mar 26, 2021

Could The China Touyun Tech Group Limited (HKG:1332) Ownership Structure Tell Us Something Useful?

If You Had Bought China Touyun Tech Group (HKG:1332) Shares A Year Ago You'd Have Earned 380% Returns

The Executive Chairman of China Touyun Tech Group Limited (HKG:1332), Liang Wang, Just Bought 8.8% More Shares

New 90-day high: HK$0.80

New 90-day high: HK$0.58

How Much Of China Touyun Tech Group Limited (HKG:1332) Do Insiders Own?

China Touyun Tech Group Limited Announces Changes to Its Board

New 90-day high: HK$0.50

New 90-day low: HK$0.29

First half earnings released

First half earnings released

China Touyun Tech Group Limited to Report First Half, 2020 Results on Aug 26, 2020

Gelir ve Gider Dağılımı

Kazanç ve Gelir Geçmişi

Serbest Nakit Akışı ve Kazanç Analizi

Geçmiş Kazanç Büyüme Analizi

Özkaynak Getirisi

Varlık Getirisi

Kullanılan Sermaye Getirisi

Geçmişte güçlü performans gösteren şirketleri keşfedin